Met Life Investment Management, LLC Nurix Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 42,539 shares of NRIX stock, worth $657,227. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,539
Previous 35,239
20.72%
Holding current value
$657,227
Previous $791,000
1.26%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$105 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$67.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$64.8 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$60 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$55.4 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $728M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...